PDF herunterladen
Thorac Cardiovasc Surg 2020; 68(08): 706-713
DOI: 10.1055/s-0039-3400471
Original Cardiovascular

Post-Coronary Artery Bypass Medications in Dialysis Patients: Do We Need to Change Strategies?

Yu-Ning Hu
1   Department of Surgery, Division of Cardiovascular Surgery, National Cheng Kung University College of Medicine, Tainan, Taiwan
,
Chwan-Yau Luo
1   Department of Surgery, Division of Cardiovascular Surgery, National Cheng Kung University College of Medicine, Tainan, Taiwan
,
Meng-Ta Tsai
1   Department of Surgery, Division of Cardiovascular Surgery, National Cheng Kung University College of Medicine, Tainan, Taiwan
,
Ting-Wei Lin
1   Department of Surgery, Division of Cardiovascular Surgery, National Cheng Kung University College of Medicine, Tainan, Taiwan
,
Chung-Dann Kan
1   Department of Surgery, Division of Cardiovascular Surgery, National Cheng Kung University College of Medicine, Tainan, Taiwan
,
Jun-Neng Roan
1   Department of Surgery, Division of Cardiovascular Surgery, National Cheng Kung University College of Medicine, Tainan, Taiwan
2   Medical Device Innovation Center, National Cheng Kung University College of Medicine, Tainan, Taiwan
3   Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
› Institutsangaben Funding National Cheng Kung University Hospital (Grant/Award Number: “NCKUH-10803027” to YNH) and National Science Institute (Grant/Award Number: “MOST 108–2314-B-006–097” to JNR).
› Weitere Informationen
    Lizenzen und Reprints Alle Artikel dieser Rubrik

Abstract

Background Coronary artery bypass grafting (CABG) is frequently performed in patients with end-stage renal disease (ESRD) together with severe coronary artery disease, after which, patients with ESRD have higher surgical risk and poorer long-term outcomes. We report our experience in patients with ESRD who survived in CABG and identify predictors of long-term outcomes.

Methods We retrospectively investigated 93 consecutive patients with ESRD who survived to discharge after isolated CABG between January 2005 and December 2016 at our institution. Long-term outcomes, including all-cause mortality after discharge, readmission due to major adverse cardiac events, and reintervention, were evaluated. Predictors affecting long-term outcomes were also analyzed.

Results The rates of freedom from all-cause mortality after discharge in 1, 3, 5, and 10 years were 92.1, 81.3, 71.9, and 34.9%, respectively. The rates of freedom from readmission due to major adverse cardiac events in 1, 3, 5, and 10 years were 90.7, 79.1, 69.9, and 55.6%, respectively. The rates of freedom from reintervention in 1, 3, 5, and 10 years were 95.3, 86.5, 79.0, and 66.6%, respectively. Postoperative β-blocker and statin use significantly improved overall long-term survival (β-blocker, p = 0.013; statin, p = 0.009). After case–control matching, patients who received statins showed better long-term survival than those without statins. The comparison of long-term survival between patients with and without β-blockers showed no significant difference after matching.

Conclusions After CABG, dialysis patients who survived to discharge had acceptable long-term overall survival. Post-CABG statin use in dialysis patients is a predictor of better long-term survival.

Keywords

coronary artery bypass grafts surgery - CABG - ischemic heart disease - angina

Statement of Ethics

The hospital's Institutional Review Board approved the study (IRB: A-ER-107–171).


Disclosure Statement

None declared.


Authors' Contributions

Conception and design of study: Chwan-Yau Luo, Jun-Neng Roan


Acquisition of data: Yu-Ning Hu, Ting-Wei Lin


Analysis and/or interpretation of data: Yu-Ning Hu, Chung-Dann Kan


Drafting the manuscript: Yu-Ning Hu


Revising the manuscript: Meng-Ta Tsai, Jun-Neng Roan


Approval of the version of the manuscript: Chwan-Yau Luo, Jun-Neng Roan




Publikationsverlauf

Eingereicht: 24. Mai 2019

Angenommen: 09. Oktober 2019

Artikel online veröffentlicht:
31. Dezember 2019

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 2018 Annual Data Report of The United States Renal Data System. 2018 . Accessed Feb 1, 2019 at: https://www.usrds.org/2018/view/Default.aspx
    PubMedGoogle Scholar
  • 2 Dewey TM, Herbert MA, Prince SL. et al. Does coronary artery bypass graft surgery improve survival among patients with end-stage renal disease?. Ann Thorac Surg 2006; 81 (02) 591-598 , discussion 598
    CrossrefPubMedGoogle Scholar
  • 3 Krabatsch T, Yeter R, Hetzer R. Coronary surgery in patients requiring chronic hemodialysis. Kidney Blood Press Res 2005; 28 (5-6): 270-274
    CrossrefPubMedGoogle Scholar
  • 4 Sunagawa G, Komiya T, Tamura N, Sakaguchi G, Kobayashi T, Murashita T. Coronary artery bypass surgery is superior to percutaneous coronary intervention with drug-eluting stents for patients with chronic renal failure on hemodialysis. Ann Thorac Surg 2010; 89 (06) 1896-1900 , discussion 1900
    CrossrefPubMedGoogle Scholar
  • 5 Trachiotis GD, Hanumara D, McKenna L, Corso P, Pfister A. Surgical revascularization after acute myocardial infarction in patients with end-stage renal disease. Eur J Cardiothorac Surg 2004; 26 (04) 671-675
    CrossrefPubMedGoogle Scholar
  • 6 Kan CD, Yang YJ. Coronary artery bypass grafting in patients with dialysis-dependent renal failure. Tex Heart Inst J 2004; 31 (03) 224-230
    PubMedGoogle Scholar
  • 7 Leontyev S, Davierwala PM, Gaube LM. et al. Outcomes of dialysis-dependent patients after cardiac operations in a single-center experience of 483 patients. Ann Thorac Surg 2017; 103 (04) 1270-1276
    CrossrefPubMedGoogle Scholar
  • 8 Witczak B, Hartmann A, Svennevig JL. Multiple risk assessment of cardiovascular surgery in chronic renal failure patients. Ann Thorac Surg 2005; 79 (04) 1297-1302
    CrossrefPubMedGoogle Scholar
  • 9 Parikh DS, Swaminathan M, Archer LE. et al. Perioperative outcomes among patients with end-stage renal disease following coronary artery bypass surgery in the USA. Nephrol Dial Transplant 2010; 25 (07) 2275-2283
    CrossrefPubMedGoogle Scholar
  • 10 Hillis LD, Smith PK, Anderson JL. et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124 (23) e652-e735
    PubMedGoogle Scholar
  • 11 Stone NJ, Robinson JG, Lichtenstein AH. et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25) (Suppl. 02) S1-S45
    CrossrefPubMedGoogle Scholar
  • 12 Sarnak MJ, Bloom R, Muntner P. et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. Am J Kidney Dis 2015; 65 (03) 354-366
    CrossrefPubMedGoogle Scholar
  • 13 Nashef SA, Roques F, Sharples LD. et al. EuroSCORE II. Eur J Cardiothorac Surg 2012; 41 (04) 734-744 , discussion 744–745
    CrossrefPubMedGoogle Scholar
  • 14 Takami Y, Tajima K, Kato W. et al. Predictors for early and late outcomes after coronary artery bypass grafting in hemodialysis patients. Ann Thorac Surg 2012; 94 (06) 1940-1945
    CrossrefPubMedGoogle Scholar
  • 15 Chen HS, Cheng CT, Hou CC, Liou HH, Lim PS. Survival and other clinical outcomes of maintenance hemodialysis patients in Taiwan: a 5-year multicenter follow-up study. Hemodial Int 2014; 18 (04) 799-808
    CrossrefPubMedGoogle Scholar
  • 16 Gibney EM, Casebeer AW, Schooley LM. et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study. Kidney Int 2005; 68 (02) 826-832
    CrossrefPubMedGoogle Scholar
  • 17 Kagawa Y, Toyofuku M, Masaoka Y. et al. Effect of statin on the 5 years clinical outcomes in dialysis patients treated with sirolimus-eluting stent. Intern Med 2014; 53 (02) 89-94
    CrossrefPubMedGoogle Scholar
  • 18 Weir MA, Herzog CA. Beta blockers in patients with end-stage renal disease-evidence-based recommendations. Semin Dial 2018; 31 (03) 219-225
    CrossrefPubMedGoogle Scholar
  • 19 Wanner C, Krane V, März W. et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353 (03) 238-248
    CrossrefPubMedGoogle Scholar
  • 20 Fellström BC, Jardine AG, Schmieder RE. et al; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360 (14) 1395-1407
    CrossrefPubMedGoogle Scholar
  • 21 Webster A, Palmer S, Ruospo M, Strippoli GF. Statins for end-stage kidney disease treated with dialysis. Nephrology (Carlton) 2015; 20 (04) 302-303
    CrossrefPubMedGoogle Scholar
  • 22 Li YH, Ueng KC, Jeng JS. et al; Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients. 2017 Taiwan lipid guidelines for high risk patients. J Formos Med Assoc 2017; 116 (04) 217-248
    CrossrefPubMedGoogle Scholar
  • 23 Barakat AF, Saad M, Abuzaid A, Mentias A, Mahmoud A, Elgendy IY. Perioperative statin therapy for patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2016; 101 (02) 818-825
    CrossrefPubMedGoogle Scholar
  • 24 Girerd N, Pibarot P, Daleau P. et al. Statins reduce short- and long-term mortality associated with postoperative atrial fibrillation after coronary artery bypass grafting: impact of postoperative atrial fibrillation and statin therapy on survival. Clin Cardiol 2012; 35 (07) 430-436
    CrossrefPubMedGoogle Scholar
  • 25 Kulik A, Ruel M. Lipid-lowering therapy and coronary artery bypass graft surgery: what are the benefits?. Curr Opin Cardiol 2011; 26 (06) 508-517
    CrossrefPubMedGoogle Scholar
  • 26 Papathanasiou A, Toumpoulis IK, Milionis HJ, Kalantzi K, Katsouras CS, Goudevenos J. Statin therapy is associated with reduced total and cardiovascular mortality after coronary artery bypass grafting surgery. Coron Artery Dis 2008; 19 (08) 619-625
    CrossrefPubMedGoogle Scholar
  • 27 Furukawa Y, Taniguchi R, Ehara N. et al; CREDO-Kyoto Investigators. Better survival with statin administration after revascularization therapy in Japanese patients with coronary artery disease: perspectives from the CREDO-Kyoto registry. Circ J 2008; 72 (12) 1937-1945
    CrossrefPubMedGoogle Scholar
  • 28 Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 2008; 118 (18) 1785-1792
    CrossrefPubMedGoogle Scholar
  • 29 Kim SH, Jeong HY, Yang DH, Kim J, Lee SY. Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: a nationwide retrospective cohort study. Sci Rep 2018; 8 (01) 9692
    CrossrefPubMedGoogle Scholar